The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.

Also called NCT03819790

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 119 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03819790
Other papers using this trial's data
  • Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial Canadian journal of diabetes, 2022-07 DOI, PubMed 35752566

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03819790. Randomized; no masking; primary purpose treatment. Start 2018-10-02 (actual); primary completion 2019-11-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
Acronym
VARIATION 2 SA
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Basal insulin glargine and lixisenatide
Intervention (Drug)
Basal insulin Basaglar/Lantus + gliclazide MR
Intervention (Drug)
Metformin
Lead sponsor
LMC Diabetes & Endocrinology Ltd. (class: other)

Record details

Record id
cardio:ct-nct03819790
Content hash
ef7b348c39601729dc23ee1d79494c2cd92a863dd20ddd9460390cb3332dae3d